Filing Flows › CG Oncology (CGON) › Q3 2025
CG Oncology (CGON) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
CG Oncology (CGON) reported revenue of $1.7M for the third quarter 2025 (Q3 2025), up 39-fold from a year earlier.
CG Oncology, Q3 2025: revenue $1.7M (39× year over year), net loss $43.8M, operating cash flow −$38.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | — | 39× |
| Operating profit | −$51.1M | — | — |
| Net earnings | −$43.8M | — | — |
| Operating cash flow | −$38.9M | — | — |
What changed
Revenue was $1.7M in Q3 2025, up 3774% year over year. Commercial and Development Revenue was the largest line at 91% of revenue. License and Collaboration Revenue added $115K year over year (up 267%), 7% of the total change.
Operating costs exceeded revenue by $51.1M, an operating margin of -3069.0%. Total costs grew 86% against revenue growth of 3774%. The fastest-growing cost line was General & admin (+168%). The quarter ended with a net loss of $43.8M.
Operating cash flow was −$38.9M. Non-cash charges added back $416K of depreciation and amortization and $7.3M of share-based compensation. Working capital and other items used $2.8M. Capital expenditures of $97K exceeded it, leaving free cash flow of −$39.0M.
Questions
What was CG Oncology's revenue in the third quarter 2025?
CG Oncology (CGON) reported revenue of $1.7M for the third quarter 2025 (Q3 2025), up 39-fold from a year earlier.
Source: CG Oncology 10-Q on SEC EDGAR.